The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: biotech

Cumberland Ends Bio IPO Drought But Prices Under Range. Next Up, Emdeon.

Cumberland Pharmaceuticals (NASDAQ: CPIX) raised $85 million in its IPO today, pricing at $17 per share.  This was less than the $19-21 per share range, but since it’s the first bio IPO since November 2007 we won’t complain. The company is planning to use the proceeds to buy late-stage or approved therapies for acute care [...]

This Week in the Twitterverse: August 8, 2009

Since I’ve been using Twitter to note short but interesting items that don’t require a whole blog post, I thought I’d post a re-cap of the week’s Tweets.  So, for those who aren’t on Twitter and haven’t been reading the @crossborderbio feed in the column to your right (or who read the blog by RSS), here’s [...]

Do the Q2 Venture Capital Numbers plus the HGS Success Indicate a Light at the End of the Tunnel for Biotech Funding?

Many of the articles and talks on biotech funding over the past year or so have lamented that public markets are closed to biotechs, and that the absence of a public exit, coupled with the preference for licensing over M&A by big pharma, would seriously dis-incentivize venture funding for biotech startups.  Two data points this [...]

$700 Million Close Opens the Doors at Teralys Capital

Teralys Capital, the fund-of-funds announced in Quebec’s budget in March, actually closed on its $700 million today and “is now ready to move ahead with its mandate to finance private venture capital funds that invest in technology companies in the life sciences, information technology and clean technology sectors.”  (I guess the extra $125 million they were [...]

Flow-Through Shares for Cleantech and Biotech in Canada

Rick Sutin, a partner at Ogilvy Renault (my home-away-from-home), has a post up at Cleantech in Canada singing the praises of flow-through shares. So far, the flow-through program in Canada has been available (mainly) to resource exploration and development companies, but we have been arguing for a while that the program would be ideal for Cleantech and [...]

Canada — and MaRS — Draw Notice on List of Biotechnology Clusters

A report at Genetic Engineering and Biotechnology News, picked up today by FierceBiotech, discusses emerging biotechnology clusters.  It’s worth excerpting the whole bit on Canada: Both Toronto and Vancouver have good, small companies, but they’re struggling for capital. They have the benefit of government support and strong universities, particularly the University of Toronto, the University [...]

The Patent Reform Act of 2009: Absent Inequitable Conduct Provisions Help Biotech

The Patent Reform Act of 2009 was introduced by Senator Patrick Leahy (D-VT) Chairman of the Senate Judiciary Committee. The bill includes Senator Orrin Hatch (R-UT) as a co-sponsor. Notably missing from the list of co-sponsors is Senator Arlen Specter (R-PA), Ranking Republican on the Judiciary Committee. Provisions relating to inequitable conduct have been removed [...]

Sibelius for HHS. Sibelius for Biotech?

The official announcement came today that Sibelius has accepted the HHS nomination.  Dani posted last week about Sibelius’ support for the Kansas Economic Growth Act, which provided $500 million in support for biotechnology in the state.  Also of note is this story (scroll down to the 3rd headline) about her Agriculture Secretary, Adrian Polansky, who also appears [...]

Sibelius and Biotech

Yes, we have all heard the rumors about Kansas Governor Kathleen Sibelius as the next HHS Secretary. How will the potential Secretary Sibelus impact the biotechnology industry? In her first term, Sibelius signed into law the Kansas Economic Growth Act, which was seen as a way to boost Kansas’ biotechnology industry. The Act allocated $500 [...]

Follow

Get every new post delivered to your Inbox.

Join 92 other followers